WO2009077864A3 - Compositions and methods of detecting tiabs - Google Patents

Compositions and methods of detecting tiabs Download PDF

Info

Publication number
WO2009077864A3
WO2009077864A3 PCT/IB2008/003836 IB2008003836W WO2009077864A3 WO 2009077864 A3 WO2009077864 A3 WO 2009077864A3 IB 2008003836 W IB2008003836 W IB 2008003836W WO 2009077864 A3 WO2009077864 A3 WO 2009077864A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
methods
assessing
tiabs
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/003836
Other languages
French (fr)
Other versions
WO2009077864A2 (en
Inventor
Bernard Bihain
Virginie Ogier
Marie Brulliard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmedi SA
Original Assignee
Transmedi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0820980-4A priority Critical patent/BRPI0820980A2/en
Priority to US12/747,945 priority patent/US9068988B2/en
Priority to EP08861905.1A priority patent/EP2235527B1/en
Priority to MX2010006484A priority patent/MX2010006484A/en
Priority to CA2709130A priority patent/CA2709130A1/en
Priority to AU2008337238A priority patent/AU2008337238B2/en
Priority to JP2010537541A priority patent/JP6076581B2/en
Priority to NZ586737A priority patent/NZ586737A/en
Priority to HK10109635.0A priority patent/HK1144319B/en
Application filed by Transmedi SA filed Critical Transmedi SA
Priority to EA201070738A priority patent/EA018597B1/en
Priority to CN200880125970.7A priority patent/CN101971026B/en
Publication of WO2009077864A2 publication Critical patent/WO2009077864A2/en
Publication of WO2009077864A3 publication Critical patent/WO2009077864A3/en
Priority to IL206225A priority patent/IL206225A0/en
Anticipated expiration legal-status Critical
Priority to ZA2010/04914A priority patent/ZA201004914B/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells bearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
PCT/IB2008/003836 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs Ceased WO2009077864A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
HK10109635.0A HK1144319B (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs
EP08861905.1A EP2235527B1 (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs
MX2010006484A MX2010006484A (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs.
CA2709130A CA2709130A1 (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs
AU2008337238A AU2008337238B2 (en) 2007-12-14 2008-12-15 Compositions and methods of detecting TIABS
JP2010537541A JP6076581B2 (en) 2007-12-14 2008-12-15 Compositions and methods for detecting TIABS
NZ586737A NZ586737A (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs
BRPI0820980-4A BRPI0820980A2 (en) 2007-12-14 2008-12-15 Compositions and methods for thiab detection
EA201070738A EA018597B1 (en) 2007-12-14 2008-12-15 COMPOSITIONS AND METHODS OF TIAB DETECTION
US12/747,945 US9068988B2 (en) 2007-12-14 2008-12-15 Compositions and methods of detecting TIABs
CN200880125970.7A CN101971026B (en) 2007-12-14 2008-12-15 Compositions and methods for detecting TIABS
IL206225A IL206225A0 (en) 2007-12-14 2010-06-07 Compositions and methods of detecting tiabs
ZA2010/04914A ZA201004914B (en) 2007-12-14 2010-07-12 Compositions and methods of detecting tiabs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301680A EP2071334A1 (en) 2007-12-14 2007-12-14 Compositions and methods of detecting TIABS
EP07301680.0 2007-12-14

Publications (2)

Publication Number Publication Date
WO2009077864A2 WO2009077864A2 (en) 2009-06-25
WO2009077864A3 true WO2009077864A3 (en) 2009-08-13

Family

ID=39473819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003836 Ceased WO2009077864A2 (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs

Country Status (14)

Country Link
US (1) US9068988B2 (en)
EP (2) EP2071334A1 (en)
JP (1) JP6076581B2 (en)
KR (1) KR101595305B1 (en)
CN (1) CN101971026B (en)
AU (1) AU2008337238B2 (en)
BR (1) BRPI0820980A2 (en)
CA (1) CA2709130A1 (en)
EA (1) EA018597B1 (en)
IL (1) IL206225A0 (en)
MX (1) MX2010006484A (en)
NZ (1) NZ586737A (en)
WO (1) WO2009077864A2 (en)
ZA (1) ZA201004914B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US9709565B2 (en) * 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
JP5640774B2 (en) 2011-01-28 2014-12-17 富士通株式会社 Information collation apparatus, information collation method, and information collation program
SI3173427T1 (en) 2011-03-31 2019-08-30 ADC Therapeutics SA, Antibodies to the kidney-bound antigen 1 and antigen-binding fragments thereof
KR102102239B1 (en) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 Method for treating breast cancer
CN108802385B (en) 2012-02-09 2022-02-08 米密德诊断学有限公司 Markers and determinants for diagnosing infection and methods of use thereof
WO2013165262A1 (en) * 2012-04-30 2013-11-07 Auckland Uniservices Limited Peptides, constructs and uses therefor
BR112017002884A2 (en) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ? computational analysis of biological data using variety and hyperplane?
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN107209184B (en) 2014-12-11 2020-04-24 米密德诊断学有限公司 Marker combinations for diagnosing multiple infections and methods of use thereof
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. RNA DETERMINANTS FOR DIFFERENTIATING BETWEEN BACTERIAL AND VIRAL INFECTIONS
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
JP6899890B2 (en) * 2016-03-18 2021-07-07 ジェンクリＧｅｎｃｌｉｓ Molecular origin of allergies
JP2019513373A (en) * 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド Neo antigen and method of using the same
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
RU2674994C2 (en) * 2016-12-29 2018-12-14 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Method for determining markers of presence of tumor t-lymphoblasts
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
TW201930340A (en) 2017-12-18 2019-08-01 美商尼恩醫療公司 Neoantigens and uses thereof
JP7523358B2 (en) * 2018-06-13 2024-07-26 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ Peptides having inhibitory activity against muscarinic M3 receptors
MX2020014243A (en) 2018-06-19 2021-05-12 Biontech Us Inc NEOANTIGENS AND THEIR USES.
US20220349010A1 (en) * 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
KR102599650B1 (en) * 2020-11-12 2023-11-08 서울대학교산학협력단 Novel lipopeptide compound, a preparing method, and a use thereof
TW202241925A (en) * 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 Peptides displayed by hla for use in immunotherapy against different types of cancers
EP4162948A1 (en) * 2021-10-05 2023-04-12 Genclis Transcription infidelity derived chimeric immunogens and uses thereof
CN114685609B (en) * 2022-04-11 2023-04-14 东北农业大学 A kind of ultrashort self-assembled antibacterial peptide FWR and its preparation method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887088A1 (en) * 2006-07-20 2008-02-13 Transmedi SA Transcription infidelity, detection and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2009532664A (en) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ Identification and use of novopeptides for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887088A1 (en) * 2006-07-20 2008-02-13 Transmedi SA Transcription infidelity, detection and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANANT SHRIKANT ET AL: "Hydrolytic nucleoside and nucleotide deamination, and genetic instability: A possible link between RNA-editing enzymes and cancer?", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, vol. 9, no. 4, 1 April 2003 (2003-04-01), pages 147 - 152, XP002411597, ISSN: 1471-4914 *
BRULLIARD MARIE ET AL: "Nonrandom variations in human cancer ESTs indicate that mRNA heterogeneity increases during carcinogenesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 18, May 2007 (2007-05-01), pages 7522 - 7527, XP002484008, ISSN: 0027-8424 *
CAPPIONE AMEDEO J ET AL: "A POTENTIAL ROLE FOR NF1 MRNA EDITING IN THE PATHOGENESIS OF NF1 TUMORS", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 60, no. 2, 1 January 1997 (1997-01-01), pages 305 - 312, XP008072803, ISSN: 0002-9297 *
FINN OLIVERA J: "Immune response as a biomarker for cancer detection and a lot more.", THE NEW ENGLAND JOURNAL OF MEDICINE 22 SEP 2005, vol. 353, no. 12, 22 September 2005 (2005-09-22), pages 1288 - 1290, XP002484010, ISSN: 1533-4406 *
HARDOUIN JULIE ET AL: "Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES JUN 2007, vol. 1107, June 2007 (2007-06-01), pages 223 - 230, XP002484009, ISSN: 0077-8923 *
KLIMEK-TOMCZAK K ET AL: "Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 94, 10 January 2006 (2006-01-10), pages 586 - 592, XP002411595, ISSN: 0007-0920 *
LESLIE D ET AL: "Autoantibodies as predictors of disease.", THE JOURNAL OF CLINICAL INVESTIGATION NOV 2001, vol. 108, no. 10, November 2001 (2001-11-01), pages 1417 - 1422, XP002484011, ISSN: 0021-9738 *
MAAS S ET AL: "Underediting of glutamate receptor GluR-B mRNA in malignant gliomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 98, no. 25, 4 December 2001 (2001-12-04), pages 14687 - 14692, XP002974829, ISSN: 0027-8424 *
TAN E M: "Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.", THE JOURNAL OF CLINICAL INVESTIGATION NOV 2001, vol. 108, no. 10, November 2001 (2001-11-01), pages 1411 - 1415, XP002484012, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
BRPI0820980A2 (en) 2015-06-23
EA201070738A1 (en) 2011-04-29
NZ586737A (en) 2014-08-29
KR20100124247A (en) 2010-11-26
EP2235527A2 (en) 2010-10-06
JP2011505825A (en) 2011-03-03
EA018597B1 (en) 2013-09-30
HK1144319A1 (en) 2011-02-11
AU2008337238A1 (en) 2009-06-25
US20110097743A1 (en) 2011-04-28
MX2010006484A (en) 2010-09-10
US9068988B2 (en) 2015-06-30
WO2009077864A2 (en) 2009-06-25
CN101971026A (en) 2011-02-09
CN101971026B (en) 2016-05-04
JP6076581B2 (en) 2017-02-15
IL206225A0 (en) 2010-12-30
CA2709130A1 (en) 2009-06-25
KR101595305B1 (en) 2016-02-18
EP2235527B1 (en) 2015-06-24
ZA201004914B (en) 2011-04-28
EP2071334A1 (en) 2009-06-17
AU2008337238B2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
WO2009077864A3 (en) Compositions and methods of detecting tiabs
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
Boyajian et al. Microbiome and human aging: probiotic and prebiotic potentials in longevity, skin health and cellular senescence
Härter et al. Nutritional and functional factors as prognostic of surgical cancer patients
Csiszar et al. Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment
Sepúlveda et al. Frailty in aging and the search for the optimal biomarker: a review
Aleksandrova et al. Circulating omentin as a novel biomarker for colorectal cancer risk: data from the EPIC–potsdam cohort study
JP2016513094A5 (en)
EP3750916A3 (en) Anti-dengue virus ns1 protein monoclonal antibodies
EP3208617A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
HK1202154A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
MX342791B (en) ELISA TEST FOR VEGF DETECTION.
MX2009003583A (en) Compositions and multiplex assays for measuring biological mediators of physiological health.
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
Melis et al. Taste changes in patients with inflammatory bowel disease: associations with PROP phenotypes and polymorphisms in the salivary protein, gustin and CD36 receptor genes
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
Franco et al. APOE genotype associates with food consumption and body composition to predict dyslipidaemia in Brazilian adults with normal-weight obesity syndrome
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
Chen et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential diagnostic markers for rebleeding in patients with esophagogastric variceal bleeding
EP2508886A3 (en) Means and methods for classifying samples of multiple sclerosis patients
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders
WO2008090177A3 (en) Diagnosis of prostate cancer
Meza-Ramos et al. High-intensity exercise promotes deleterious cardiovascular remodeling in a high-cardiovascular-risk model: a role for oxidative stress
Chi et al. Coexistence of hereditary spherocytosis with SPTB P. Trp1150 gene variant and Gilbert syndrome: A case report and literature review
Wobeto et al. Haptoglobin polymorphism and diabetic retinopathy in Brazilian patients

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880125970.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08861905

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2709130

Country of ref document: CA

Ref document number: MX/A/2010/006484

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010537541

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008337238

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008861905

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 586737

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4315/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107015486

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201070738

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2008337238

Country of ref document: AU

Date of ref document: 20081215

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12747945

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0820980

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100614